Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TFFP
- Price
- 0.07
- Stock movement up
- +- (%)
- Company name
- Tff Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 288.80K
- Ent value
- 1.62M
- Price/Sales
- 0.16
- Price/Book
- 0.09
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 17.08%
- 1 year return
- -98.90%
- 3 year return
- -92.53%
- 5 year return
- -77.98%
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
TFFP does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.16 |
| Price to Book | 0.09 |
| EV to Sales | 0.91 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 4.44M |
| EPS (TTM) | -4.24 |
| FCF per share (TTM) | -2.89 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.78M |
| Gross profit (TTM) | 1.37M |
| Operating income (TTM) | -19.02M |
| Net income (TTM) | -18.52M |
| EPS (TTM) | -4.24 |
| EPS (1y forward) | -3.77 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 76.90% |
| Operating margin (TTM) | -1068.19% |
| Profit margin (TTM) | -1040.11% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.61M |
| Net receivables | 0.00 |
| Total current assets | 3.51M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.70M |
| Total assets | 7.08M |
| Accounts payable | 1.64M |
| Short/Current long term debt | 52.40K |
| Total current liabilities | 3.94M |
| Total liabilities | 3.94M |
| Shareholder's equity | 3.14M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -12.59M |
| Capital expenditures (TTM) | 46.39K |
| Free cash flow (TTM) | -12.64M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -590.38% |
| Return on Assets | -261.68% |
| Return on Invested Capital | -571.30% |
| Cash Return on Invested Capital | -389.79% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.07 |
| Daily high | 0.07 |
| Daily low | 0.07 |
| Daily Volume | 0K |
| All-time high | 493.75 |
| 1y analyst estimate | 30.00 |
| Beta | 1.32 |
| EPS (TTM) | -4.24 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| TFFP | S&P500 | |
| Current price drop from All-time high | -99.99% | -3.00% |
| Highest price drop | -99.99% | -56.47% |
| Date of highest drop | 26 Feb 2025 | 9 Mar 2009 |
| Avg drop from high | -64.33% | -11.07% |
| Avg time to new high | 37 days | 12 days |
| Max time to new high | 1031 days | 1805 days |
COMPANY DETAILS
Marketcap
288.80K
Marketcap category
Small-cap
Description
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
Employees
19
Website
Investor relations
-
SEC filings
CEO
Glenn R. Mattes
Country
USA
City
Austin
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner